View ValuationSudeep Pharma 향후 성장Future 기준 점검 2/6Sudeep Pharma은 연간 수입과 매출이 각각 10.4%와 19.4% 증가할 것으로 예상되고 EPS는 연간 10.2%만큼 증가할 것으로 예상됩니다.핵심 정보10.4%이익 성장률10.21%EPS 성장률Chemicals 이익 성장16.2%매출 성장률19.4%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트17 Aug 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesValuation Update With 7 Day Price Move • Aug 11Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹1,108, the stock trades at a forward P/E ratio of 62x. Average forward P/E is 26x in the Chemicals industry in India.New Risk • Aug 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.공고 • Aug 05Sudeep Pharma Limited Announces Board ChangesSudeep Pharma Limited at its 37th AGM held on 4 August 2026 approved appointment of Mr. Milin Mehta as a Director (Non-Executive and Non- Independent) and to Change the Remuneration of Mr. Ajay Shrirang Kandelkar (DIN: 10773491) as Whole Time Director with effect from 1st April 2026.공고 • Jul 25Sudeep Pharma Limited to Report Q1, 2027 Results on Aug 04, 2026Sudeep Pharma Limited announced that they will report Q1, 2027 results on Aug 04, 2026Reported Earnings • Jul 14Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: ₹15.50 (up from ₹12.79 in FY 2025). Revenue: ₹6.42b (up 28% from FY 2025). Net income: ₹1.73b (up 25% from FY 2025). Profit margin: 27% (in line with FY 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.3%. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India.공고 • Jul 11Sudeep Pharma Limited, Annual General Meeting, Aug 04, 2026Sudeep Pharma Limited, Annual General Meeting, Aug 04, 2026, at 11:00 Indian Standard Time.Valuation Update With 7 Day Price Move • Jun 17Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹870, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 29x in the Chemicals industry in India.분석 기사 • May 29Sudeep Pharma's (NSE:SUDEEPPHRM) Solid Earnings May Rest On Weak FoundationsFollowing the solid earnings report from Sudeep Pharma Limited ( NSE:SUDEEPPHRM ), the market responded by bidding up...Reported Earnings • May 23Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: ₹15.50 (up from ₹12.79 in FY 2025). Revenue: ₹6.71b (up 34% from FY 2025). Net income: ₹1.73b (up 25% from FY 2025). Profit margin: 26% (down from 28% in FY 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.3%. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India.공고 • May 14Sudeep Pharma Limited to Report Q4, 2026 Results on May 21, 2026Sudeep Pharma Limited announced that they will report Q4, 2026 results on May 21, 2026Reported Earnings • Feb 07Third quarter 2026 earnings released: EPS: ₹4.29 (vs ₹4.07 in 3Q 2025)Third quarter 2026 results: EPS: ₹4.29 (up from ₹4.07 in 3Q 2025). Revenue: ₹1.79b (up 14% from 3Q 2025). Net income: ₹474.6m (up 7.4% from 3Q 2025). Profit margin: 27% (down from 28% in 3Q 2025). The decrease in margin was driven by higher expenses.공고 • Feb 02Sudeep Pharma Limited to Report Q3, 2026 Results on Feb 06, 2026Sudeep Pharma Limited announced that they will report Q3, 2026 results on Feb 06, 2026Reported Earnings • Dec 20Second quarter 2026 earnings released: EPS: ₹4.20 (vs ₹4.07 in 2Q 2025)Second quarter 2026 results: EPS: ₹4.20 (up from ₹4.07 in 2Q 2025). Revenue: ₹1.73b (up 9.7% from 2Q 2025). Net income: ₹457.5m (up 3.5% from 2Q 2025). Profit margin: 27% (down from 28% in 2Q 2025). The decrease in margin was driven by higher expenses.공고 • Dec 15Sudeep Pharma Limited to Report Q2, 2026 Results on Dec 19, 2025Sudeep Pharma Limited announced that they will report Q2, 2026 results on Dec 19, 2025Board Change • Dec 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Raghunandan Rao was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.이익 및 매출 성장 예측NSEI:SUDEEPPHRM - 애널리스트 향후 추정치 및 과거 재무 데이터 (INR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수3/31/20289,3812,187-344N/A23/31/20277,2761,954435N/A16/30/20266,7561,826N/AN/AN/A3/31/20266,4231,729-158696N/A12/31/20256,1751,682N/AN/AN/A9/30/20255,6071,495-233412N/A6/30/20255,1251,366-339306N/A3/31/20255,0201,387-155487N/A3/31/20244,5931,332157657N/A3/31/20234,28762312484N/A3/31/20223,446498-604-26N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: SUDEEPPHRM 의 연간 예상 수익 증가율(10.4%)이 saving rate(6.9%)보다 높습니다.수익 vs 시장: SUDEEPPHRM 의 연간 수익(10.4%)이 Indian 시장(16.8%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: SUDEEPPHRM 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: SUDEEPPHRM 의 수익(연간 19.4%)이 Indian 시장(연간 11.2%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: SUDEEPPHRM 의 수익(연간 19.4%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: SUDEEPPHRM의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YMaterials 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/21 18:15종가2026/08/21 00:00수익2026/06/30연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Sudeep Pharma Limited는 2명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Sanjesh JainICICI Securities Ltd.Swarnendu BhushanPrabhudas Lilladher Pvt Ltd.
Valuation Update With 7 Day Price Move • Aug 11Investor sentiment improves as stock rises 27%After last week's 27% share price gain to ₹1,108, the stock trades at a forward P/E ratio of 62x. Average forward P/E is 26x in the Chemicals industry in India.
New Risk • Aug 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
공고 • Aug 05Sudeep Pharma Limited Announces Board ChangesSudeep Pharma Limited at its 37th AGM held on 4 August 2026 approved appointment of Mr. Milin Mehta as a Director (Non-Executive and Non- Independent) and to Change the Remuneration of Mr. Ajay Shrirang Kandelkar (DIN: 10773491) as Whole Time Director with effect from 1st April 2026.
공고 • Jul 25Sudeep Pharma Limited to Report Q1, 2027 Results on Aug 04, 2026Sudeep Pharma Limited announced that they will report Q1, 2027 results on Aug 04, 2026
Reported Earnings • Jul 14Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: ₹15.50 (up from ₹12.79 in FY 2025). Revenue: ₹6.42b (up 28% from FY 2025). Net income: ₹1.73b (up 25% from FY 2025). Profit margin: 27% (in line with FY 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.3%. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India.
공고 • Jul 11Sudeep Pharma Limited, Annual General Meeting, Aug 04, 2026Sudeep Pharma Limited, Annual General Meeting, Aug 04, 2026, at 11:00 Indian Standard Time.
Valuation Update With 7 Day Price Move • Jun 17Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹870, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 29x in the Chemicals industry in India.
분석 기사 • May 29Sudeep Pharma's (NSE:SUDEEPPHRM) Solid Earnings May Rest On Weak FoundationsFollowing the solid earnings report from Sudeep Pharma Limited ( NSE:SUDEEPPHRM ), the market responded by bidding up...
Reported Earnings • May 23Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: ₹15.50 (up from ₹12.79 in FY 2025). Revenue: ₹6.71b (up 34% from FY 2025). Net income: ₹1.73b (up 25% from FY 2025). Profit margin: 26% (down from 28% in FY 2025). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 1.3%. Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in India.
공고 • May 14Sudeep Pharma Limited to Report Q4, 2026 Results on May 21, 2026Sudeep Pharma Limited announced that they will report Q4, 2026 results on May 21, 2026
Reported Earnings • Feb 07Third quarter 2026 earnings released: EPS: ₹4.29 (vs ₹4.07 in 3Q 2025)Third quarter 2026 results: EPS: ₹4.29 (up from ₹4.07 in 3Q 2025). Revenue: ₹1.79b (up 14% from 3Q 2025). Net income: ₹474.6m (up 7.4% from 3Q 2025). Profit margin: 27% (down from 28% in 3Q 2025). The decrease in margin was driven by higher expenses.
공고 • Feb 02Sudeep Pharma Limited to Report Q3, 2026 Results on Feb 06, 2026Sudeep Pharma Limited announced that they will report Q3, 2026 results on Feb 06, 2026
Reported Earnings • Dec 20Second quarter 2026 earnings released: EPS: ₹4.20 (vs ₹4.07 in 2Q 2025)Second quarter 2026 results: EPS: ₹4.20 (up from ₹4.07 in 2Q 2025). Revenue: ₹1.73b (up 9.7% from 2Q 2025). Net income: ₹457.5m (up 3.5% from 2Q 2025). Profit margin: 27% (down from 28% in 2Q 2025). The decrease in margin was driven by higher expenses.
공고 • Dec 15Sudeep Pharma Limited to Report Q2, 2026 Results on Dec 19, 2025Sudeep Pharma Limited announced that they will report Q2, 2026 results on Dec 19, 2025
Board Change • Dec 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Raghunandan Rao was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.